<DOC>
	<DOCNO>NCT00002013</DOCNO>
	<brief_summary>To evaluate safety , pharmacokinetics , immunologic parameter neurocognitive data three dosage AS-101 combination zidovudine ( AZT ) patient AIDS AIDS relate complex ( ARC ) .</brief_summary>
	<brief_title>A Safety , Pilot Pharmacokinetics Neurocognitive Study AS-101 Combination With Zidovudine AIDS/ARC Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ammonium trichloro ( dioxoethylene-O , O'- ) tellurate</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Zidovudine ( AZT ) . Aerosolized pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Allowed ONLY permission WyethAyerst medical monitor : Standard therapy infection develop study period . Oral acyclovir . Nystatin . Ketoconazole . Immunomodulators . Specific therapy malignancy ( include Kaposi 's sarcoma ) . Patients must follow : Diagnosis AIDS AIDS relate complex ( ARC ) . Provide inform write consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active opportunistic infection malignancy require treatment study entry . Prior history psychiatric illness head injury judgment neuropsychologist would impair interpretation neurocognitive data . Evidence central nervous system ( CNS ) opportunistic infection malignancy . Serious underlie medical problem , include insulin dependent diabetes mellitus , unstable ASHD ( atherosclerotic heart disease ) uncontrolled hypertension , may complicate interpretation treatment result . Dementia . Evidence = &gt; 2 + proteinuria study entry . Concurrent Medication : Excluded without permission WyethAyerst medical monitor : Immunomodulators . Specific therapy malignancy ( include Kaposi 's sarcoma ) . Patients follow exclude : Active opportunistic infection malignancy require treatment study entry . Prior history psychiatric illness head injury judgment neuropsychologist would impair interpretation neurocognitive data . Evidence condition list Patient Exclusion Coexisting Conditions . Active substance abuse . Unlikely unable comply requirement protocol . Prior Medication : Excluded within 8 week study entry : Immunomodulators . Antiviral therapy , except zidovudine . Excluded within 2 week study entry : Intravenous oral acyclovir . Excluded within 3 month study entry : Ribavirin . Required : Zidovudine dose = &gt; 1000 mg/day least 6 week prior study entry . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 1990</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>ammonium trichloro ( dioxoethylene-O , O'- ) tellurute</keyword>
	<keyword>Zidovudine</keyword>
</DOC>